Advertisement
Advertisement
SGMT
Sagimet Biosciences Inc. Series A Common Stock
10.89
USDSponsored
+0.06
+0.55%
Nov 10, 15:59 UTC -5
Closed
After-Market
10.88
-0.01
-0.05%
Sagimet Biosciences Inc. Series A Common Stock (SGMT) Earnings
SGMT Earnings Reports
Positive Surprise Ratio
SGMT beat 8 of 13 last estimates.
62%
Next Report
In 2 Days
Date of Next Report
Nov 12, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.26
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
--
/-35.00%
Sagimet Biosciences Inc. Series A Common Stock earnings per share and revenue
On Aug 11, 2026, SGMT reported earnings of -0.26 USD per share (EPS) for Q2 26, missing the estimate of -0.25 USD, resulting in a -3.54% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of -0.26 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Sagimet Biosciences Inc. Series A Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Sagimet Biosciences Inc. Series A Common Stock reported EPS of -$0.26, missing estimates by -3.54%, and revenue of $0.00, 0% as expectations.
How did the market react to Sagimet Biosciences Inc. Series A Common Stock's Q2 2026 earnings?
The stock price moved -- 0%, changed from $10.58 before the earnings release to $10.58 the day after.
When is Sagimet Biosciences Inc. Series A Common Stock expected to report next?
The next earning report is scheduled for Nov 12, 2026.
What are the forecasts for Sagimet Biosciences Inc. Series A Common Stock's next earnings report?
Based on 7
analysts, Sagimet Biosciences Inc. Series A Common Stock is expected to report EPS of -$0.26 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.